Regentis Biomaterials Ltd. (RGNT) Stock Overview
Explore Regentis Biomaterials Ltd.’s financial performance, market position, analyst ratings, and future outlook.
Regentis Biomaterials Ltd. (RGNT)
Key Financials
Key Financials
Market Cap
15.9M
P/E Ratio
N/A
EPS (TTM)
$-24.16
ROE
N/A
RGNT Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Regentis Biomaterials Ltd. (RGNT) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of C+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 53.06, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of N/A and a market capitalization of 15.9M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.